Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals develops clinical-stage immunotherapy medicines built around rose bengal sodium, a synthetic small molecule in the halogenated xanthene family. News about PVCT centers on its PV-10 and PV-305 formulations, research publications, preclinical disease models, and clinical-program activity across oncology, dermatology, and ophthalmology.
Recurring updates also cover VisiRose, the company’s ocular-therapeutics subsidiary, and rose bengal photodynamic antimicrobial therapy for infectious keratitis and other eye infections. Additional company announcements address proof-of-concept work in wound healing, infectious disease, tissue repair, hematology, and vaccine-adjuvant research, along with annual-meeting and other public-company governance matters.
Provectus Biopharmaceuticals (OTCQB: PVCT) and its ophthalmology subsidiary VisiRose announced issuance of U.S. Patent No. 12,661,335 for a light-independent rose bengal sodium (RBS) antibacterial eye drop targeting Gram-positive bacterial keratitis, including drug-resistant strains such as MRSA and vancomycin-resistant Enterococcus.
The patent covers defined, tear-compatible formulations, biofilm eradication in light and dark, and is exclusively licensed to VisiRose.
Provectus Biopharmaceuticals (OTCQB: PVCT) launched Veripure™, an open science program providing qualified researchers worldwide free access to PV-10, formulated from pharmaceutical-grade rose bengal sodium (RBS) API used in clinical trials.
The program offers unrestricted study design and publications, distinguishes PV-10 from variable-purity commercial rose bengal, leverages cGMP/QbD manufacturing accepted by multiple regulators for a historical Phase 3 melanoma trial, and builds on WHO’s recommended non-proprietary name RBS.
Provectus Biopharmaceuticals (OTCQB: PVCT) announced that its 2026 annual stockholder meeting will be held in person and via Zoom webinar. The meeting takes place on Thursday, June 18, 2026, at 4:00 p.m. ET in Knoxville, with proxy materials available on the company’s website.
Provectus Biopharmaceuticals (OTCQB: PVCT) reported preclinical data for oral PV-10 in an orthotopic bladder cancer model in humanized mice. Across five active treatment arms, oral PV-10 monotherapy ranked highest using a weighted framework assessing response, survival, safety, data quality, and translational potential.
Oral PV-10 cut Day 23 tumor burden about 40% versus vehicle control and showed the best tolerability, with a body weight nadir of −1.9%. Two long-term survivors in oral PV-10 arms had no gross bladder tumor at Day 45 necropsy, a finding not seen in controls or anti-PD-1 monotherapy.
Provectus (OTCQB: PVCT) highlights four Bascom Palmer Eye Institute posters at ARVO 2026 on rose bengal photodynamic antimicrobial therapy (RB-PDAT) and a fifth multicenter RCT abstract (REAGIR).
Key data: REAGIR was a 330-patient sham-controlled RCT using a single RB-PDAT cycle; Fusarium subgroup (63%) showed a 0.17-line directional visual benefit (p=0.1); rose bengal inhibited MRSA biofilm by 74%; repeat/high-fluence RB-PDAT produced 100% 24-hour cyst inhibition and 50% activity at 21 days.
Provectus (OTCQB: PVCT) will hold its 2026 Annual Meeting of Stockholders on June 18, 2026 at 4:00 p.m. ET at Perkins Place, 525 Portland Street, Knoxville, Tennessee.
Perkins Place is Provectus’s planned new headquarters: a 22,941 sq ft renovated building on 3.23 acres, reacquired in fall 2025 via a partnership with the East Tennessee Foundation. The move is intended to help manage costs and allow future expansion.
Provectus (OTCQB: PVCT) highlighted independent porcine preclinical data showing PV-10 (rose bengal sodium) in a Pluronic hydrogel shifted wound immunity toward a pro-regenerative state. At day 120 post-burn PV-10 increased pan-macrophage and CD206 expression (p=0.0034; p=0.0277) and reduced CD3+ T cells (p=0.0360) versus saline, with no rise in 4-HNE oxidative markers.
The study found measurable activity after repeated topical dosing without controlled green-light activation, and noted formulation/dosing adjustments may further differentiate effects.
Provectus (OTCQB: PVCT) reported independent preclinical research (Oct 9, 2025) showing PV-10 (rose bengal sodium) activates the STING pathway, stabilizing STING dimerization, upregulating pro-inflammatory cytokines/chemokines, and boosting IFN‑gamma from antigen-primed T cells. The study suggests PV-10 could serve as a differentiated vaccine adjuvant alternative to aluminum salts, emulsions, saponins, and nucleic acid fragments and may help ~10% of vaccine non-responders for hepatitis B.
Company highlights market optionality: vaccine adjuvant market projected to exceed $2B by 2030, global vaccine sales >b$70B by 2030, oncology vaccine market >b$10B by 2032, and immune checkpoint therapies >b$40B.
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched a preclinical study of its lead drug PV-10 for bladder cancer treatment. The study, conducted by TD2, will evaluate both oral and intravesical monotherapy applications, as well as combination therapy with an anti-PD-1 checkpoint inhibitor.
The research aims to generate translational data to guide future clinical development and support broader immuno-oncology applications. Results are expected in Q1 2026. The study's findings will potentially enable expansion of PV-10's investigational new drug application for both site-specific and systemic administration.
Provectus Biopharmaceuticals (OTCQB: PVCT) announced the publication of preclinical research on PV-10 for head and neck squamous cell carcinoma (HNSCC) in Molecular Cancer Therapeutics. The research, conducted by Dr. Christine Chung's team at Moffitt Cancer Center, revealed novel mechanistic findings about PV-10's ability to trigger immunogenic cell death in HNSCC through endoplasmic reticulum stress and apoptosis.
The company plans to initiate a Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt Cancer Center later in 2025. PV-10 is Provectus's investigational cancer immunotherapy formulated from pharmaceutical-grade rose bengal sodium (RBS).